Skip to content
    Font Size

    Is a New Crohn’s Disease Treatment on the Horizon?

    WebMD Health News
    Reviewed by Louise Chang, MD

    Oct. 17, 2012 -- A drug used to treat psoriasis may provide a much-needed option for people with bad cases of Crohn’s disease.

    In the new study, some people with moderate to severe Crohn's given Stelara (ustekinumab) began to see improvements in their symptoms within six weeks.

    Crohn's disease is an inflammatory bowel disease marked by inflammation and damage of any part of the digestive tract.

    Inflammation plays a central role in both Crohn’s and the skin disease psoriasis. Stelara blocks two proteins that promote inflammation. A commonly used class of drugs for Crohn's blocks the activity of another protein that promotes inflammation called tumor necrosis factor (TNF). Treatments in this class include Cimzia, Humira, and Remicade.

    But not everyone with Crohn’s is helped by TNF drugs, and some who do well at first stop responding to them.

    “About 60% of people with Crohn’s disease will have an initial response to TNF drugs and of those, half will lose their response over the course of the year,” says researcher William J. Sandborn, MD. He is the chief of the division of gastroenterology at the University of California San Diego School of Medicine. They can still try additional TNF drugs if they haven't been helped by one, but surgery is often their last resort, he says.

    The new findings are “very encouraging and bode well that this drug will eventually become a new treatment option for people with Crohn’s,” Sandborn says.

    As of now, Stelara is being studied in clinical trials of Crohn’s disease across the U.S.

    The new study included 526 people with moderate to severe Crohn's that was resistant to TNF-blocker drugs. Some participants were given one intravenous dose of Stelara, and another dose was injected every eight weeks for 36 weeks; other participants were given a placebo.

    Some people given the new drug began to improve within six weeks of therapy. Those who responded to Stelara after the initial dose were more likely to enter remission at 22 weeks.

    Six people treated with Stelara developed a serious infection, and one person developed basal cell skin cancer. Both infections and skin cancer are also considered risks with the TNF-blockers due to how these drugs affect the immune system.

    Today on WebMD

    man holding his stomach
    Get the facts on common problems.
    blueberries in a palm
    Best and worst foods.
    woman shopping
    Learn what foods to avoid.
    fresh and dried plums
    Will it help constipation?
    diverticuliltis illustration
    couple eating at cafe
    sick child
    Woman blowing bubble gum

    Send yourself a link to download the app.

    Loading ...

    Please wait...

    This feature is temporarily unavailable. Please try again later.


    Now check your email account on your mobile phone to download your new app.

    Woman with crohns in pain
    Woman with stomach pain
    diet for diverticulitis
    what causes diarrhea